Major Depressive Disorder (MDD) is a leading cause of disability worldwide, creating a high
medical and socioeconomic burden. There is a growing interest in the biological …

Mood disorders are common, chronic, recurrent mental illnesses that affect the lives of
millions of individuals worldwide. To date, the monoaminergic systems (serotonergic …

Context Existing therapies for major depression have a lag of onset of action of several
weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have …

Context Increasing evidence indicates that major depressive disorder (MDD) is associated
with altered function of the major excitatory and inhibitory neurotransmitters glutamate and γ …

Despite the complexity and heterogeneity of mood disorders, basic and clinical research
studies have begun to elucidate the pathophysiology of depression and to identify rapid …

Major depression is a common, severe, chronic, and often life-threatening illness. There is a
growing appreciation that, far from being a disease with purely psychological manifestations …

The monoamine theory has implicated abnormalities in serotonin and norepinephrine in the
pathophysiology of major depression and bipolar illness and contributed greatly to our …

Existing treatments for major depressive disorder (MDD) usually take weeks to months to
achieve their antidepressant effects, and a significant number of patients do not have …

Tianeptine is a clinically used antidepressant that has drawn much attention, because this
compound challenges traditional monoaminergic hypotheses of depression. It is now …

Mood disorders such as bipolar disorder and major depressive disorder are common,
chronic, and recurrent conditions affecting millions of individuals worldwide. Existing …